Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 20221-20230 Newer>

The Motley Fool January 29, 2007 Brian Lawler	The Paris Hilton of Drug Stocks Yet another rumor about a potential merger for Bristol-Myers. Who is the winner in a Bristol-Myers and Sanofi-Aventis merger? It obviously depends on the price Sanofi is willing to pay. Investors, take note.
The Motley Fool January 29, 2007 Jeremy MacNealy	Fool on Call: McDonald's Going Starbucks? In its most recent quarterly earnings conference call, the leadership at McDonald's introduced a subtle shift of focus. The king of quick serve will continue to push for premium in 2007.
The Motley Fool January 29, 2007 David Lee Smith	Will All Newspapers Fold? Rich old men vie to buy fading newspapers. Does anyone else care? Given their business prowess, why would the billionaires be interested in owning withering daily newspapers? Investors, take note.
The Motley Fool January 29, 2007 David Lee Smith	Will All Newspapers Fold? Part 2 Dying newspapers still generate cash -- but only so much, for so long. The takeaway for smart investors is simple: Avoid this group of investments at all costs.
The Motley Fool January 29, 2007 Rich Smith	Foolish Forecast: L-3's Communicating The defense and security specialist is set to report its fourth-quarter and full-year 2006 earnings results. Investors, here is what you can expect to see.
The Motley Fool January 29, 2007	CDW Needs to Reboot: Fool by Numbers The computer and technology direct marketer released fourth-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool January 29, 2007 Brian Lawler	No Dicey Results for Cubist The stock price may be down, but Cubist Pharmaceuticals is looking strong.
The Motley Fool January 29, 2007 Will Frankenhoff	Pump Up Your Position in PetroChina PetroChina's shares should provide high-octane returns in 2007.
The Motley Fool January 29, 2007 Brian Lawler	Bristol-Myers Blames the Generic Again The fourth quarter's financial results are dominated by generic competition.
The Motley Fool January 29, 2007 Tom Taulli	Check Point at the Tipping Point After some key M&A deals, it's time to capitalize on improved product offerings. All this could certainly provide some catalysts for the stock in the next year or so.
<Older 20221-20230 Newer> Return to current articles.